George Touma Highlights DCB-BIF Trial: Drug-Coated Balloons Improve Outcomes in Coronary Bifurcation PCI
George Touma, Interventional Cardiologist at St George Private Cardiology, posted on LinkedIn:
” What is the DCB-BIF Trial?
The DCB-BIF (Drug-Coated Balloon in Bifurcations) trial is the first well powered, multicenter randomized study comparing drug-coated balloon (DCB) angioplasty versus conventional non-compliant balloon (NCB) angioplasty for the side branch (SB) in patients with true but “simple” coronary bifurcation lesions treated using a provisional stenting strategy.
Conducted across 22 centers in China, Indonesia, Italy, and Korea, it enrolled 784 patients.
Study Design and Patients
• Included patients with true bifurcations (Medina 1,1,1; 0,1,1; or 1,0,1) and SB ostial stenosis ≥70% after main vessel (MV) stenting and proximal optimization (POT).
• Randomized 1:1 into two groups:
– DCB arm – SB treated with a paclitaxel-coated balloon
– NCB arm – SB treated with a standard non-compliant balloon
• Primary endpoint: 1-year MACE (cardiac death, target-vessel MI, clinically driven TLR).
• Patients: median age 65 years, 23% women.
Key Findings
MACE at 1 year:
• 7.2% in the DCB group
• 12.5% in the NCB group
Benefit driven by lower target-vessel MI.
Rates of cardiac death, TLR, procedural success, two-stent crossover, all-cause death, and stent thrombosis were similar.
Interpretation and Significance
• DCB for SB angioplasty improves outcomes compared to conventional ballooning in this scenario.
• As the first large RCT powered for clinical outcomes, DCB-BIF provides evidence for incorporating DCBs into bifurcation PCI strategies.
Broader Context and Research
• Before DCB-BIF: evidence was limited to small RCTs and meta-analyses focused on angiographic outcomes like late lumen loss (LLL). These suggested better SB patency and possible MI reduction, but lacked power.
• Meta-analysis of 5 RCTs (~1,255 patients): DCBs reduced MI risk (RR = 0.56; p=0.01), though no significant differences in overall MACE, TLR, or mortality.
The Five RCTs used in this meta analysis:
1. Herrador et al., 2013 (Spain) – Non-randomized (NRCT) study using SeQuent Please paclitaxel-eluting balloon.
2. Zong et al., 2018 (China) – RCT, SeQuent Please paclitaxel-eluting balloon.
3. Zhang et al., 2019 (China) – NRCT, SeQuent Please paclitaxel-eluting balloon.
4. Jing et al., 2020 (China) – RCT, Bingo paclitaxel-eluting balloon.
5. Bu et al., 2021 (China) – RCT, DCB (unspecified brand).
• PEPCAD-BIF trial (~64 patients): showed less late lumen loss with DCB vs plain balloons.
• Ongoing trials (e.g., OCVC-BIF) are testing additional DCB use after kissing balloon inflation versus standard approaches, aiming to refine bifurcation PCI strategies.
Take-Home Message
The DCB-BIF trial establishes DCB angioplasty as a clinically superior side-branch strategy in provisional bifurcation PCI – delivering fewer MIs. Its my default strategy.”
Stay updated with Hemostasis Today.
-
Feb 24, 2026, 16:18Salmaan Dalvi: Mapping Rare Diseases Across East and Central Africa
-
Feb 24, 2026, 16:16Wolfgang Miesbach: Game‑Changing Data on Intensive FVIII Replacement in Haemophilia A with Hypertrophic Synovium
-
Feb 24, 2026, 16:01Is It Safe to Briefly Stop Anticoagulation After VTE? – RPTH Journal
-
Feb 24, 2026, 15:58Anastasia Conti: Honored to Receive the Roche Foundation Grant for Independent Research in Onco-Hematology
-
Feb 24, 2026, 15:55Courtney Lawrence: Targeted Donor Screening Reduces Transfusion-Transmitted Babesia Cases
-
Feb 24, 2026, 15:30Aswin K Mohan: Practical Tips for Preparing Before, During, and After Blood Donation
-
Feb 24, 2026, 15:24Stéphanie Forté: The Hidden Burden of Stroke in Adults Living with Sickle Cell Disease
-
Feb 24, 2026, 15:13Tagreed Alkaltham: Equity in Emergency Care Through a Blood Bank Lens
-
Feb 24, 2026, 14:57Joseph Raffaele: Can Improving Mitochondrial Quality in Immune Cells Alter Immune Aging Markers?